Copyright
©The Author(s) 2022.
World J Gastroenterol. Sep 14, 2022; 28(34): 4959-4972
Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.4959
Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.4959
Ref. | Study type | Biologics exposure | Number of patients (total number of patients in the study) | Regimen of CAP | Rate of remission | Rate of steroid-free remission |
Cabriada et al[35], 2012 | Retrospective study (results of nationwide Spanish registry) | IFX | 33 (total: 142 SD) | GMA (95% of the Pts), 1-10 sessions (median 5 sessions) | 37% (all Pts), no differences in clinical remission were found among those Pts with previous thiopurine or IFX failure | |
Dignass et al[36], 2016 | Single-arm, open-label, multicentre trial | TNF-α | 37 (total: 86 SD) | GMA (5-10 sessions, 1 session/wk) | 27.8% (Pts who failed on TNF-α), 40.3% (Pts who failed on immunosuppressants | |
Yamamoto et al[37], 2018 | Retrospective study | (1) IFX; and (2) ADA | (1) 31; and (2) 36 (total: 593) | GMA (5 sessions, 1 to 5 sessions/wk), 5 or 6 GMA were added in Pts who did not achieve clinical remission | 31% (Pts exposed to biologics), 48% (Pts unexposed to biologics), P = 0.01 |
- Citation: Iizuka M, Etou T, Sagara S. Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy. World J Gastroenterol 2022; 28(34): 4959-4972
- URL: https://www.wjgnet.com/1007-9327/full/v28/i34/4959.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i34.4959